GSK’s performance in 2025 exemplified the strengthening of all the fundamentals of the strategy, demonstrating the consistent new standard to which the company is now operating.
We have a clear strategy to develop a high-quality portfolio of specialty medicines and vaccines. The priority now is delivery and overall operational execution.
We delivered another year of strong performance with growth in sales, core operating profit and earnings driven by Specialty Medicines.
Group turnover
£32.7bn
AER +4%, CER +7%
Specialty medicines turnover
£13.5bn
AER +14%, CER +17%
Vaccines turnover
£9.2bn
AER -%, CER +2%
General medicines turnover
£10bn
AER -4%, CER -1%
Total operating profit
£7.9bn
AER +97%, CER >100%
Core operating profit
£9.8bn
AER +7%, CER +11%
% CER and core results are non-IFRS measures, the definitions of which and reconciliations to the nearest IFRS measure can be found on pages 95 to 96 of the 2025 Annual Report.
Research and development
We continued to strengthen our late-stage pipeline with organic R&D delivery and targeted business development, supporting future growth.
£8bn
Innovation sales of products launched, or with major lifecycle innovation expansion, in the last five years
5
Major product approvals in 2025
7
Pivotal trial starts
17
Assets in phase III/registration
58
Assets in the pipeline
14
New collaborations and acquisitions
Responsible business
We are committed to addressing issues that matter for society and for the long-term performance of our company. Our Responsible Business Performance Rating tracks progress across our six focus areas: access; global health and health security; environment; inclusion; ethical standards; and product governance.
Of our Responsible Business Performance Rating metrics ‘met’ or ‘exceeded’ in 2025
99m
Doses of critical vaccines delivered to Gavi to help protect vulnerable populations in lower-income countries
14%
Reduction in operational carbon emissions since 2023 (Scope 1 & 2)
Culture and people
We measure progress on embedding our culture through our employee surveys. For the past three years, our employee engagement scores have consistently been higher than 80% and remain above industry benchmarks.
